Current and Future Treatment Strategies
Presented by the Johns Hopkins University School of Medicine.
for the Glioblastoma Multiforme Patient:
Highlights From WFNO and SNO
Supported by educational grants from Arbor Pharmaceuticals, LLC and Novocure.
Highly invasive and aggressive, glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults. Despite a significant change in the standard of care for patients with GBM over the past decade, treatment outcomes have not seen a drastic improvement. Clinicians face numerous challenges when managing patients with this fatal disease. GBMs are highly heterogeneous in both appearance and molecular biology, and; clinicians often struggle with analyzing new literature on the efficacy and safety of approved treatment options and assessing the role of emerging treatment options and clinical biomarkers in developing treatment regimens for their patients. The rapid progression of GBM necessitates timely and well-informed decision making on the part of the clinician, which can be better achieved through education on the most current treatment options and strategies.
The goal of this activity is to provide participants with the most up-to-date and current information on treatment options, patient prognosis, and understanding the literature on the treatment and management of patients with GBM.
This activity is designed neurosurgeons, surgical oncologists, neuro-oncologists, and radiation oncologists. No prerequisites required.
After completing this activity, the participant will demonstrate the ability to:
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
- ANALYZE up-to-date evidence on current and emerging treatment options for initial and recurrent glioblastoma.
- IDENTIFY the emerging role of clinical biomarkers in treatment selection and prognosis for glioblastoma patients.
- EVALUATE recent research on the treatment of low grade gliomas.
Accreditation Statement — The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement — The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
After reviewing this online activity, participants may receive a certificate by receiving a score of 70% or higher on the CME test and completing an evaluation. A certificate of participation will be available online immediately following successful completion of the activity.
The estimated time to complete this activity: 60 minutes.
Release date: July 30, 2014. Expiration date: July 30, 2015.
Stuart Grossman, MD (Course Director)
Medicine and Neurological Surgery
Professor of Medicine, Oncology, and Neurological Surgery
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
John B. Fiveash, MD
Vice Chairman for Academic Programs
Department of Radiation Oncology
Robert Y. Kim Outstanding Educator
University of Alabama
Patrick Yung Wen, MD
Director, Neuro-oncology Division
Harvard Medical School
Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:
Participating Faculty Disclosures
Dr Grossman reports serving as a member of the Scientific Advisory Board for Midatech; serving as a member of the Data Safety Monitoring Committee for a phase III study for Roche; serving as a member of the Data Safety Monitoring Committee for a phase II study for MedImmune, LLC; performing research funding of clinical studies for Erimos Pharmaceuticals, LLC; and is a patent holder and chief medical officer exploring new treatment for cancer pain in preclinical studies for Axxia Pharmaceuticals, LLC.
No other speakers have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).
Dr Grossman reports serving as a member of the Data Safety Monitoring Committee for a phase III study for Roche; serving as a member of the Data Safety Monitoring Committee for a phase II study for MedImmune, LLC; and is a patent holder and chief medical officer exploring new treatment for cancer pain in preclinical studies for Axxia Pharmaceuticals, LLC.
Dr Wen reports serving as a consultant for and receiving honoraria from Merck & Co, Inc; and serving on the advisory board for Novartis AG.
No planner has indicated that they have any financial interests or relationships with a commercial entity.
No other planners have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
Off-Label Product Discussion
No speaker has indicated that he/she will reference unlabeled/unapproved uses of drugs or products.
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based activity. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME program. CME collects only the information necessary to provide you with the services that you request.
I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.
I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Johns Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person’s health or treatment that identifies the person. I also understand that while I am participating in this capacity I will be treated as a temporary member of Johns Hopkins for purposes of the Privacy Regulations only.
I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.
I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.
“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”
Johns Hopkins University School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/09)
Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.
Current and Future Treatment Strategies for the Glioblastoma Multiforme Patient:
Please complete the pretest, listen to and watch the presentation, and complete the post-test and evaluation to receive CME credit for this activity. A certificate of participation will be available online immediately following successful completion of the activity.
Highlights from WFNO and SNO
Stuart Grossman, MD; John B. Fiveash, MD; Patrick Yung Wen, MD
|Johns Hopkins Advanced Studies in Medicine (ISSN-1558-0334), is published by Galen Publishing, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2012 by Galen Publishing. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of The Healthcare Media Group, LLC.